VIDEO: Integrating study findings into clinical practice ‘remains to be seen’

A number of presentations during this year’s ASCO20 Virtual Scientific Program featured data on the efficacy and safety of immunotherapy combinations for the treatment of metastatic non-small cell lung cancer.

In this video, Julia K. Rotow, MD, medical oncologist at the Dana-Farber Cancer Institute, shared her perspective on some of the findings.

“Two of these are partially related, looking at the combination of nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) for metastatic disease in the first-line setting,” Rotow said. “We saw updated survival data from CheckMate 227, as well as data from CheckMate 9LA.”

Although findings from these trials led to FDA approvals, she noted that it can be a challenge to incorporate study findings into clinical practice.

“It remains to be seen how this will integrate into practice,” she said.

Reference:

Ramalingam SS, et al. Abstract 9500. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.
Reck M, et al. Abstract 9501. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview

Disclosures: Rotow reports a consultant/advisory role with AstraZeneca, travel, accommodations and expenses from Array and Eli Lilly, and honoraria from Takeda.

Take Homes in Lung Cancer

Read more

VIDEO: Integrating study findings into clinical practice ‘remains to be seen’

Reference:

Related Content